Pharmaceuticals, Biotechnology & Life Sciences

Johnson & Johnson’s strategic playbook: stabilizing stock amid market volatility, expanding medical‑device robotics, countering patent cliffs, and leveraging tiered pricing and M&A for long‑term growth.

Gilead’s FDA acceptance of Yeztugo’s sNDA marks a key milestone for its once‑weekly HIV PrEP, while insider share sales confirm routine liquidity activity and highlight investor confidence.

Jiangsu Hengrui’s June 2026 clearance marks a key clinical‑trial milestone for its next‑gen drug, signaling regulatory progress and potential investor upside while keeping the specifics under wraps.

Eurofins Scientific’s June share‑repurchase signals confidence, boosts shareholder value and underlines its strategy to grow in personalized medicine and global bio‑analysis markets.

Discover how EISAI’s diversified EGFR‑targeted pipeline—spanning small molecules, bispecific antibodies, and ADCs—positions the company to lead the next wave of precision oncology therapies.

Genmab’s focus on antibody‑based therapies, especially epcoritamab’s early success, offers hospitals a promising yet complex option for improving DLBCL outcomes while navigating reimbursement and cost‑efficiency challenges.

Vertex Pharmaceuticals’ recent Rule 144 filing shows a routine insider sale of 4,062 shares—no impact on its CF drug pipeline or market position.

Neurocrine Biosciences shows new long‑term data for VYKAT XR and CR NESSITY, boosting market access, pricing strategy, and M&A prospects in rare endocrine diseases.

Incyte’s latest clinical data show Tafasitamab and Zilurgisertib could hit $300M+ revenue by 2028, driving strong M&A interest and reshaping oncology and rare‑disease markets.

QIAGEN expands its QIAcuity digital‑PCR ecosystem with new gene‑expression panels, a 12‑target one‑step multiplex kit, and automated reporting, boosting sensitivity, throughput, and regulatory compliance for diagnostics and biopharma research.